A Phase I, randomized, double-blind, placebo-controlled single and multiple ascending dose program study to investigate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of its oral LSD1-MAOB dual selective inhibitor ORY-2001 in healthy subjects

Trial Profile

A Phase I, randomized, double-blind, placebo-controlled single and multiple ascending dose program study to investigate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of its oral LSD1-MAOB dual selective inhibitor ORY-2001 in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs ORY 2001 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 24 Jul 2017 According to an Oryzon media release, with the approval of the Spanish Medicines Agency (AEMPS), an additional cohort of volunteers was added to be administered at a higher dose of ORY-2001 to complete the hematological safety profile of the product, as well as two additional cohorts to determine the levels of the drug in cerebrospinal fluid.
    • 24 Jul 2017 Final results published in an Oryzon media release.
    • 24 Jul 2017 Final results from this trial trial have been presented at the Alzheimer's Association International Conference (AAIC-2017), according to an Oryzon media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top